Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Hydrophobicity Modulated Antibacterial Small Molecule Eradicates Biofilm with Potent Efficacy against Skin-infections.

Konai MM, Barman S, Issa R, MacNeil S, Adhikary U, De K, Monk PN, Haldar J.

ACS Infect Dis. 2020 Feb 14. doi: 10.1021/acsinfecdis.9b00334. [Epub ahead of print]

PMID:
32058691
2.

Inhibition of Tetraspanin Functions Impairs Human Papillomavirus and Cytomegalovirus Infections.

Fast LA, Mikuličić S, Fritzen A, Schwickert J, Boukhallouk F, Hochdorfer D, Sinzger C, Suarez H, Monk PN, Yáñez-Mó M, Lieber D, Florin L.

Int J Mol Sci. 2018 Oct 2;19(10). pii: E3007. doi: 10.3390/ijms19103007.

3.

Monocyte Subsets Have Distinct Patterns of Tetraspanin Expression and Different Capacities to Form Multinucleate Giant Cells.

Champion TC, Partridge LJ, Ong SM, Malleret B, Wong SC, Monk PN.

Front Immunol. 2018 Jun 8;9:1247. doi: 10.3389/fimmu.2018.01247. eCollection 2018.

4.

A role for the tetraspanin proteins in Salmonella infection of human macrophages.

Hassuna NA, Monk PN, Ali F, Read RC, Partridge LJ.

J Infect. 2017 Aug;75(2):115-124. doi: 10.1016/j.jinf.2017.06.003. Epub 2017 Jun 8.

PMID:
28602860
5.

Tspan2: a tetraspanin protein involved in oligodendrogenesis and cancer metastasis.

Yaseen IH, Monk PN, Partridge LJ.

Biochem Soc Trans. 2017 Apr 15;45(2):465-475. doi: 10.1042/BST20160022. Review.

6.

Peptides from Tetraspanin CD9 Are Potent Inhibitors of Staphylococcus Aureus Adherence to Keratinocytes.

Ventress JK, Partridge LJ, Read RC, Cozens D, MacNeil S, Monk PN.

PLoS One. 2016 Jul 28;11(7):e0160387. doi: 10.1371/journal.pone.0160387. eCollection 2016.

7.

Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.

Croker DE, Monk PN, Halai R, Kaeslin G, Schofield Z, Wu MC, Clark RJ, Blaskovich MA, Morikis D, Floudas CA, Cooper MA, Woodruff TM.

Immunol Cell Biol. 2016 Sep;94(8):787-95. doi: 10.1038/icb.2016.43. Epub 2016 Apr 25.

8.

Distinct regions of the large extracellular domain of tetraspanin CD9 are involved in the control of human multinucleated giant cell formation.

Hulme RS, Higginbottom A, Palmer J, Partridge LJ, Monk PN.

PLoS One. 2014 Dec 31;9(12):e116289. doi: 10.1371/journal.pone.0116289. eCollection 2014.

9.

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.

Halai R, Bellows-Peterson ML, Branchett W, Smadbeck J, Kieslich CA, Croker DE, Cooper MA, Morikis D, Woodruff TM, Floudas CA, Monk PN.

Eur J Pharmacol. 2014 Dec 15;745:176-81. doi: 10.1016/j.ejphar.2014.10.041. Epub 2014 Oct 30.

10.

C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and β-arrestin recruitment.

Croker DE, Halai R, Kaeslin G, Wende E, Fehlhaber B, Klos A, Monk PN, Cooper MA.

Immunol Cell Biol. 2014 Aug;92(7):631-9. doi: 10.1038/icb.2014.32. Epub 2014 Apr 29.

11.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

12.

Wild-type but not mutant SOD1 transgenic astrocytes promote the efficient generation of motor neuron progenitors from mouse embryonic stem cells.

Christou YA, Ohyama K, Placzek M, Monk PN, Shaw PJ.

BMC Neurosci. 2013 Oct 17;14:126. doi: 10.1186/1471-2202-14-126.

13.

Changes and regulation of the C5a receptor on neutrophils during septic shock in humans.

Unnewehr H, Rittirsch D, Sarma JV, Zetoune F, Flierl MA, Perl M, Denk S, Weiss M, Schneider ME, Monk PN, Neff T, Mihlan M, Barth H, Gebhard F, Ward PA, Huber-Lang M.

J Immunol. 2013 Apr 15;190(8):4215-25. doi: 10.4049/jimmunol.1200534. Epub 2013 Mar 11.

14.

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors.

Klos A, Wende E, Wareham KJ, Monk PN.

Pharmacol Rev. 2013 Jan;65(1):500-43. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):466.

PMID:
23383423
15.

Heterogeneity in the responses of human lung mast cells to stem cell factor.

Lewis A, Wan J, Baothman B, Monk PN, Suvarna SK, Peachell PT.

Clin Exp Allergy. 2013 Jan;43(1):50-9. doi: 10.1111/cea.12045.

PMID:
23278880
16.

C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay.

Reis ES, Chen H, Sfyroera G, Monk PN, Köhl J, Ricklin D, Lambris JD.

J Immunol. 2012 Nov 15;189(10):4797-805. doi: 10.4049/jimmunol.1200834. Epub 2012 Oct 5.

17.

Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis.

Pavlovski D, Thundyil J, Monk PN, Wetsel RA, Taylor SM, Woodruff TM.

FASEB J. 2012 Sep;26(9):3680-90. doi: 10.1096/fj.11-202382. Epub 2012 May 31.

PMID:
22651932
18.

De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation.

Bellows-Peterson ML, Fung HK, Floudas CA, Kieslich CA, Zhang L, Morikis D, Wareham KJ, Monk PN, Hawksworth OA, Woodruff TM.

J Med Chem. 2012 May 10;55(9):4159-68. doi: 10.1021/jm201609k. Epub 2012 Apr 20.

19.

Tetraspanins: gateways for infection.

Monk PN, Partridge LJ.

Infect Disord Drug Targets. 2012 Feb;12(1):4-17. Review.

PMID:
22034932
20.

A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function.

Sargsyan SA, Blackburn DJ, Barber SC, Grosskreutz J, De Vos KJ, Monk PN, Shaw PJ.

BMC Neurosci. 2011 Sep 23;12:91. doi: 10.1186/1471-2202-12-91.

21.

Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to human epithelial cells.

Green LR, Monk PN, Partridge LJ, Morris P, Gorringe AR, Read RC.

Infect Immun. 2011 Jun;79(6):2241-9. doi: 10.1128/IAI.01354-10. Epub 2011 Apr 4.

22.

The role of tetraspanins in fusion.

Fanaei M, Monk PN, Partridge LJ.

Biochem Soc Trans. 2011 Apr;39(2):524-8. doi: 10.1042/BST0390524. Review.

PMID:
21428932
23.

Contrasting effects of cerebrospinal fluid from motor neuron disease patients on the survival of primary motor neurons cultured with or without glia.

Barber SC, Wood-Allum CA, Sargsyan SA, Walsh T, Cox LE, Monk PN, Shaw PJ.

Amyotroph Lateral Scler. 2011 Jul;12(4):257-63. doi: 10.3109/17482968.2011.560672. Epub 2011 Mar 3.

PMID:
21366496
24.

The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9.

Gutiérrez-López MD, Gilsanz A, Yáñez-Mó M, Ovalle S, Lafuente EM, Domínguez C, Monk PN, González-Alvaro I, Sánchez-Madrid F, Cabañas C.

Cell Mol Life Sci. 2011 Oct;68(19):3275-92. doi: 10.1007/s00018-011-0639-0. Epub 2011 Mar 2.

PMID:
21365281
25.

Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections.

Hassuna N, Monk PN, Moseley GW, Partridge LJ.

BioDrugs. 2009;23(6):341-59. doi: 10.2165/11315650-000000000-00000. Review.

PMID:
19894777
26.

Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1.

Sargsyan SA, Blackburn DJ, Barber SC, Monk PN, Shaw PJ.

Neuroreport. 2009 Oct 28;20(16):1450-5. doi: 10.1097/WNR.0b013e328331e8fa.

27.

Distinct roles for tetraspanins CD9, CD63 and CD81 in the formation of multinucleated giant cells.

Parthasarathy V, Martin F, Higginbottom A, Murray H, Moseley GW, Read RC, Mal G, Hulme R, Monk PN, Partridge LJ.

Immunology. 2009 Jun;127(2):237-48. doi: 10.1111/j.1365-2567.2008.02945.x.

28.

Complement component 5a (C5a).

Manthey HD, Woodruff TM, Taylor SM, Monk PN.

Int J Biochem Cell Biol. 2009 Nov;41(11):2114-7. doi: 10.1016/j.biocel.2009.04.005. Epub 2009 Apr 11. Review.

PMID:
19464229
29.

Astrocyte function and role in motor neuron disease: a future therapeutic target?

Blackburn D, Sargsyan S, Monk PN, Shaw PJ.

Glia. 2009 Sep;57(12):1251-64. doi: 10.1002/glia.20848. Review.

PMID:
19373940
30.

Complement factors C3a and C5a have distinct hemodynamic effects in the rat.

Proctor LM, Moore TA, Monk PN, Sanderson SD, Taylor SM, Woodruff TM.

Int Immunopharmacol. 2009 Jun;9(6):800-6. doi: 10.1016/j.intimp.2009.03.002. Epub 2009 Mar 12.

PMID:
19285573
31.

The human complement fragment receptor, C5L2, is a recycling decoy receptor.

Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN.

Mol Immunol. 2009 Mar;46(6):1149-62. doi: 10.1016/j.molimm.2008.11.001. Epub 2008 Dec 18.

32.

The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.

Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG.

J Immunol. 2008 Dec 15;181(12):8727-34.

33.

Complement C5a receptors in the pituitary gland: expression and function.

Francis K, Lewis BM, Monk PN, Ham J.

J Endocrinol. 2008 Dec;199(3):417-24. doi: 10.1677/JOE-08-0110.

PMID:
19020281
34.

Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms.

Barreiro O, Zamai M, Yáñez-Mó M, Tejera E, López-Romero P, Monk PN, Gratton E, Caiolfa VR, Sánchez-Madrid F.

J Cell Biol. 2008 Nov 3;183(3):527-42. doi: 10.1083/jcb.200805076. Epub 2008 Oct 27.

35.

Embryonic stem cells and prospects for their use in regenerative medicine approaches to motor neurone disease.

Christou YA, Moore HD, Shaw PJ, Monk PN.

Neuropathol Appl Neurobiol. 2007 Oct;33(5):485-98. Review.

PMID:
17854436
36.

Function, structure and therapeutic potential of complement C5a receptors.

Monk PN, Scola AM, Madala P, Fairlie DP.

Br J Pharmacol. 2007 Oct;152(4):429-48. Epub 2007 Jul 2. Review.

37.

Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response.

Wright AJ, Higginbottom A, Philippe D, Upadhyay A, Bagby S, Read RC, Monk PN, Partridge LJ.

Mol Immunol. 2007 Apr;44(10):2507-17. Epub 2007 Jan 26.

38.

The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding.

Scola AM, Higginbottom A, Partridge LJ, Reid RC, Woodruff T, Taylor SM, Fairlie DP, Monk PN.

J Biol Chem. 2007 Feb 9;282(6):3664-71. Epub 2006 Dec 11.

39.

Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines.

Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A.

J Biol Chem. 2006 Dec 22;281(51):39088-95. Epub 2006 Oct 26.

40.

ALS: life and death in a bad neighborhood.

Monk PN, Shaw PJ.

Nat Med. 2006 Aug;12(8):885-7. No abstract available.

PMID:
16892030
41.

Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration.

Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, de Vos K, Pollitt S, Williams HM, Shiels IA, Monk PN, Taylor SM.

FASEB J. 2006 Jul;20(9):1407-17.

PMID:
16816116
42.

Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1.

Ho SH, Martin F, Higginbottom A, Partridge LJ, Parthasarathy V, Moseley GW, Lopez P, Cheng-Mayer C, Monk PN.

J Virol. 2006 Jul;80(13):6487-96.

43.

Tetraspanins in viral infections: a fundamental role in viral biology?

Martin F, Roth DM, Jans DA, Pouton CW, Partridge LJ, Monk PN, Moseley GW.

J Virol. 2005 Sep;79(17):10839-51. Review. No abstract available.

44.

Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis.

Sargsyan SA, Monk PN, Shaw PJ.

Glia. 2005 Sep;51(4):241-53. Review.

PMID:
15846792
45.

C5L2 is a functional receptor for acylation-stimulating protein.

Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, Cianflone K.

J Biol Chem. 2005 Jun 24;280(25):23936-44. Epub 2005 Apr 14.

46.

Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.

Higginbottom A, Cain SA, Woodruff TM, Proctor LM, Madala PK, Tyndall JD, Taylor SM, Fairlie DP, Monk PN.

J Biol Chem. 2005 May 6;280(18):17831-40. Epub 2005 Jan 20.

47.

Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.

Huber-Lang M, Sarma JV, Rittirsch D, Schreiber H, Weiss M, Flierl M, Younkin E, Schneider M, Suger-Wiedeck H, Gebhard F, McClintock SD, Neff T, Zetoune F, Bruckner U, Guo RF, Monk PN, Ward PA.

J Immunol. 2005 Jan 15;174(2):1104-10.

48.

Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation.

Barreiro O, Yáñez-Mó M, Sala-Valdés M, Gutiérrez-López MD, Ovalle S, Higginbottom A, Monk PN, Cabañas C, Sánchez-Madrid F.

Blood. 2005 Apr 1;105(7):2852-61. Epub 2004 Dec 9.

PMID:
15591117
49.

Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?

Davison KL, Andrews N, White JM, Ramsay ME, Crowcroft NS, Rushdy AA, Kaczmarski EB, Monk PN, Stuart JM.

Arch Dis Child. 2004 Mar;89(3):256-60.

50.

Structural requirements for the inhibitory action of the CD9 large extracellular domain in sperm/oocyte binding and fusion.

Higginbottom A, Takahashi Y, Bolling L, Coonrod SA, White JM, Partridge LJ, Monk PN.

Biochem Biophys Res Commun. 2003 Nov 7;311(1):208-14.

PMID:
14575715

Supplemental Content

Support Center